KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Retained Earnings (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Retained Earnings for 9 consecutive years, with $38000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 95.87% year-over-year to $38000.0, compared with a TTM value of $38000.0 through Dec 2025, down 95.87%, and an annual FY2025 reading of $38000.0, down 95.87% over the prior year.
  • Retained Earnings was $38000.0 for Q4 2025 at Biocryst Pharmaceuticals, down from $1.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $2.3 million in Q3 2024 and bottomed at -$1.7 billion in Q2 2024.
  • Average Retained Earnings over 3 years is -$819.2 million, with a median of -$754.0 million recorded in 2023.
  • The sharpest move saw Retained Earnings skyrocketed 100.14% in 2024, then crashed 95.87% in 2025.
  • Year by year, Retained Earnings stood at -$1.7 billion in 2023, then soared by 100.05% to $921000.0 in 2024, then plummeted by 95.87% to $38000.0 in 2025.
  • Business Quant data shows Retained Earnings for BCRX at $38000.0 in Q4 2025, $1.1 million in Q3 2025, and $1.6 million in Q2 2025.